Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical News Today (MNT)Combining 2 Cholesterol Drugs May Shrink Artery Plaque More Effectively, Trial Finds

⚠️ Small Study / Early Comparative Evidence

The FLOWPROMOTE randomized trial compared two cholesterol-lowering regimens in 104 Danish adults with stable chest pain and coronary artery narrowing exceeding 50%. None had previously taken statins. Participants received atorvastatin 40 mg daily or rosuvastatin 40 mg plus ezetimibe 10 mg daily for 18 months. Combination therapy produced greater LDL cholesterol reduction and coronary plaque regression. Coronary CT angiography measured plaque changes at baseline, nine months and 18 months; cardiovascular event reductions were not established.


Clinical Considerations

  • Total coronary plaque volume decreased by 21.1% with combination therapy, compared with 13.6% with atorvastatin alone.
  • Total plaque regression occurred in 90% of combination-treated participants, compared with 75% receiving atorvastatin.
  • LDL cholesterol decreased by 65% versus 38%; the combination group reached an average of 42.5 mg/dL.
  • Noncalcified plaque volume decreased by 28.2% with combination therapy, compared with 20% with atorvastatin.
  • Noncalcified plaque decreased in 51 of 52 combination-treated participants, compared with 39 participants receiving atorvastatin.
  • Calcified plaque increased modestly in both groups. The article describes this as potentially reflecting plaque stabilization rather than worsening atherosclerosis.

Practice Applications

  • The lead author attributed greater plaque regression primarily to greater LDL cholesterol reduction, rather than a specific effect of the medications themselves.
  • The article states that these findings do not mean everyone with high cholesterol needs two medications; treatment depends on individual clinical factors.
  • The article identifies larger, longer-term studies as necessary to determine whether plaque changes translate into fewer heart attacks, strokes or other cardiovascular events.
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form